The distal hinge of the reactive site loop and its proximity - A target to modulate plasminogen activator inhibitor-1 activity

被引:37
作者
Bijnens, AP
Gils, A
Stassen, JM
Komissarov, AA
Knockaert, I
Brouwers, E
Shore, JD
Declerck, PJ
机构
[1] Katholieke Univ Leuven, Fac Pharmaceut Sci, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium
[2] Boehringer Ingelheim Pharma KG, Cardiovasc Pharmacol, D-88397 Biberach, Germany
[3] Henry Ford Hlth Ctr, Div Biochem Res, Detroit, MI 48202 USA
关键词
D O I
10.1074/jbc.M103077200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The serpin plasminogen activator inhibitor type 1 (PAI-1) plays a regulatory role in various physiological processes (e.g. fibrinolysis and pericellular proteolysis) and forms a potential target for therapeutic interventions. In this study we identified the epitopes of three PAI-1 inhibitory monoclonal antibodies (MA-44E4, MA-42A2F6, and MA-56A7C10). Differential cross-reactivities of these monoclonals with PAI-1 from different species and sequence alignments between these PAI-1s, combined with the three-dimensional structure, revealed several charged residues as possible candidates to contribute to the respective epitopes. The production, characterization, and subsequent evaluation of a variety of alanine mutants using surface plasmon resonance revealed that the residues His(185), Arg(186), and Arg(187) formed the major sites of interaction for MA-44E4. In contrast, the epitopes of MA-42A2F6 and MA-56A7C10 were found to be conformational. The epitope of MA-42A2F6 comprises residues Lys(243) and Glu(350), whereas the epitope of MA-56A7C10 comprises residues Glu(242), Lys(243), Glu(244), Glu(350) Asp(355) and Arg(356). The participation of Glu(350), Asp(355), and Arg(356) provides a molecular explanation for the differential exposure of this epitope in the different conformations of PAI-1 and for the effect of these antibodies on the kinetics of the formation of the initial PAI-1-proteinase complexes. The localization of the epitopes of MA-44E4, MA42A2F6, and MA-56A7C10 elucidates two previously unidentified molecular mechanisms to modulate PAI-1 activity and opens new perspectives for the rational development of PAI-1 neutralizing compounds.
引用
收藏
页码:44912 / 44918
页数:7
相关论文
共 57 条
  • [21] CDNA CLONING OF HUMAN-PLASMINOGEN ACTIVATOR INHIBITOR FROM ENDOTHELIAL-CELLS
    GINSBURG, D
    ZEHEB, R
    YANG, AY
    RAFFERTY, UM
    ANDREASEN, PA
    NIELSEN, L
    DANO, K
    LEBO, RV
    GELEHRTER, TD
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1986, 78 (06) : 1673 - 1680
  • [22] Defining epitopes: It's not as easy as it seems
    Greenspan, NS
    Di Cera, E
    [J]. NATURE BIOTECHNOLOGY, 1999, 17 (10) : 936 - 937
  • [23] HEKMAN CM, 1985, J BIOL CHEM, V260, P11581
  • [24] HOESS RH, 1994, J IMMUNOL, V153, P724
  • [25] Structure of a serpin-protease complex shows inhibition by deformation
    Huntington, JA
    Read, RJ
    Carrell, RW
    [J]. NATURE, 2000, 407 (6806) : 923 - 926
  • [26] Jonsson U., 1992, ADV BIOSENSORS, V2, P291, DOI DOI 10.1016/B978-1-85617-161-8.50079-3
  • [27] PATHOPHYSIOLOGY OF FIBRINOLYSIS
    JUHANVAGUE, I
    ALESSI, MC
    DECLERCK, PJ
    [J]. BAILLIERES CLINICAL HAEMATOLOGY, 1995, 8 (02): : 329 - 343
  • [28] KEIJER J, 1991, BLOOD, V78, P401
  • [29] KRUITHOF EKO, 1984, BLOOD, V64, P907
  • [30] SERPIN-PROTEASE COMPLEXES ARE TRAPPED AS STABLE ACYL-ENZYME INTERMEDIATES
    LAWRENCE, DA
    GINSBURG, D
    DAY, DE
    BERKENPAS, MB
    VERHAMME, IM
    KVASSMAN, JO
    SHORE, JD
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (43) : 25309 - 25312